Anecdotally, some people who switched from semaglutide to tirzepatide report that their appetite, which had started returning somewhat on semaglutide, decreased again on tirzepatide
Insulin dose reduction of 20 to 50% at triple agonist initiation is consistent with the approach used in tirzepatide trials: the SURPASS-5 trial (N=475) reduced insulin glargine by 20% at tirzepatide initiation, which reduced hypoglycemia without sacrificing glycemic control
112,113 Several clinical studies support the cardiovascular benefits of GLP-1 RAs, as there is evidence from meta-analyses of cardiovascular outcome trials illustrating that GLP-1 RA therapy lowers the risk of major adverse cardiovascular events by 14% and all-cause mortality by 12% in patients with T2D
It can help you lose weight by reducing calorie intake, increasing energy expenditure, and improving your metabolism
Statistics are sourced from peer-reviewed studies, government agencies, and authoritative research organizations as cited